


Data Sheet

| | |
|---------------------------|--|
| Product Name: | VER-246608 |
| Cat. No.: | CS-0011787 |
| CAS No.: | 1684386-71-7 |
| Molecular Formula: | C ₂₈ H ₂₃ CIF ₂ N ₄ O ₄ |
| Molecular Weight: | 552.96 |
| Target: | PDHK |
| Pathway: | Metabolic Enzyme/Protease |
| Solubility: | DMSO : 100 mg/mL (180.84 mM; Need ultrasonic) |



BIOLOGICAL ACTIVITY:

VER-246608 is a potent and ATP-competitive inhibitor of **pyruvate dehydrogenase kinase (PDK)** with IC₅₀s of 35 nM, 40 nM, 84 nM, and 91 nM for **PDK-1, PDK-3, PDK-2, and PDK-4**, respectively. IC₅₀ & Target: IC₅₀: 35 nM (PDK-1), 40 nM (PDK-3), 84 nM (PDK-2), 91 nM (PDK-4)^[1] **In Vitro:** VER-246608 is a novel pan-isoform ATP competitive inhibitor of PDK. VER-246608 demonstrates similar potency across all four PDK isoforms in a DELFIA-based enzyme functional assay in the sub 100 nM range. In terms of cellular biomarker modulation, VER-246608 suppresses the phosphorylation of the Ser²⁹³ residue of E1α (phosphorylated by all four PDK isozymes) with IC₅₀ values of 266 nM. Treatment of PC-3 cells with 9 μM and 27 μM VER-246608 results in a 21% and 42% reduction, respectively, in media L-lactate levels following a 1 h incubation. VER-246608 also decreases D-glucose consumption at the same concentrations that result in reduced L-lactate production. An approximately 50% reduction in spheroid volume is achieved at concentrations of 10 μM and above, suggesting an increase in VER-246608 potency compared to monolayer growth^[1].

PROTOCOL (Extracted from published papers and Only for reference)

Kinase Assay: ^[1]DELFLIA assay reagents (assay buffer, wash buffer, enhancement solution and anti-rabbit IgG-Eu-N1 secondary antibody) and plates are used. Test compounds are subjected to a 10 point tripling dilution in DMSO, diluted in MOPS buffer (60 mM MOPS pH7.2, 15 mM Magnesium acetate, 60 mM KCl) and added to the enzyme mix (10 nM PDK-1, 2 and 3 or 20 nM PDK-4, 300 nM E1, 0.1 mg/mL BSA, 1 mM DTT) in 96-well V-bottom plates. The reaction is initiated by the addition of ATP to a final concentration of 5 μM followed by a 1 h incubation at 30°C. The reaction is then stopped by the addition of STOP solution (50 mM Carbonate-Bicarbonate Buffer, pH 9.6), and then transferred to 96 well DELFLIA yellow plates. The plates are then sealed and incubated o/n at 4°C. Detection and quantification of p(Ser²⁹³)E1α levels is then achieved through incubation with anti-p(Ser²⁹³)E1α primary antibody followed by anti-rabbit secondary IgG-Eu-N1 antibody and addition of enhancement solution. The time-resolved fluorescent signal is then measured using a Victor2 plate reader. The data is fitted by non-linear regression using XLFIT4 within a custom ABASE (IDBS) protocol in order to determine IC₅₀ values^[1].

Cell Assay: ^[1]Compound cytotoxicity is determined using the Sulforhodamine B assay for cells cultured as a monolayer. For spheroid growth experiments, **PC-3 cells** are seeded (500 cells/well) into 96 well round bottom plates in RPMI-1640 media containing 2.5% (w/v) Matrigel. The resultant spheroids are treated with **VER-246608 (2.5, 5, 10, 20, and 40 μM)** 48 h post-seeding. Spheroid volumes are determined by obtaining diameter measurements from images taken on a Zeiss Axiovert 200 M inverted microscope using the axiovision software^[1].

References:

[1]. Moore JD, et al. VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and

induces context-dependent cytostasis in cancer cells. Oncotarget. 2014 Dec 30;5(24):12862-76.

CAIndexNames:

Benzamide, N-[4-(2-chloro-5-methyl-4-pyrimidinyl)phenyl]-N-[[4-[[[(2,2-difluoroacetyl)amino]methyl]phenyl]methyl]-2,4-dihydroxy-

SMILES:

O=C(C1=CC=C(O)C=C1O)N(CC2=CC=C(CNC(C(F)F)=O)C=C2)C(C=C3)=CC=C3C4=NC(Cl)=NC=C4C

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA